FIN 423 final33333
84
Statement of Financial position Amount in Taka Amount in Taka Amount in Taka Amount in Taka Amount in Taka Amount in Taka 2007 2008 2009 2010 2011 2012 Assets Property plant and equipment At cost/revalution 1,327,151,308.00 1,669,956,000.00 1,829,790,619.00 1,813,315,763.00 2,545,580,924.00 2,975,419,918.00 Accumulated depreciation 467,726,369.00 549,379,587.00 654,029,893.00 57,071,200.00 214,159,844.00 402,190,536.00 859,424,939.00 1,120,576,413.00 1,175,760,726.00 1,756,244,563.00 2,331,421,080.00 2,573,229,382.00 Capital work-in-progress 213,870,224.00 135,098,300.00 106,130,728.00 678,876,604.00 611,541,022.00 889,671,313.00 1,073,295,163.00 1,255,674,713.00 1,281,891,454.00 2,435,121,167.00 2,942,962,102.00 3,462,900,695.00 Intangible assets - - - 2,335,201.00 1,816,269.00 1,297,337.00 Long-term investment 536,629,241.00 670,267,741.00 877,288,030.00 1,447,691,662.00 1,197,263,603.00 1,407,597,771.00 Non-current assets 1,609,924,404.00 1,925,942,454.00 2,159,179,484.00 3,885,148,030.00 4,142,041,974.00 4,871,795,803.00 Inventories 1,091,397,629.00 2,085,053,250.00 1,596,524,690.00 1,716,072,609.00 1,770,481,777.00 2,128,984,396.00 Trade receivables 898,891,044.00 1,304,815,553.00 1,161,296,363.00 1,017,539,096.00 1,131,611,820.00 1,292,368,456.00 Other receivables 136,565,703.00 81,605,053.00 69,510,356.00 134,442,146.00 138,454,704.00 107,406,234.00 Advances, deposits and prepayments 179,761,041.00 245,796,966.00 368,143,911.00 414,326,518.00 522,847,653.00 460,184,564.00 Advances income tax 205,661,524.00 177,028,869.00 283,104,430.00 222,974,570.00 122,788,615.00 150,489,441.00 Inter-company receivable 551,416,377.00 862,058,775.00 1,169,264,620.00 2,141,326,463.00 3,045,084,692.00 4,033,776,402.00 Cash and cash equivalents 57,195,473.00 211,924,637.00 717,864,023.00 154,440,135.00 223,659,923.00 161,461,711.00 Assets classified as held for sale - 18,601,750.00 - - - - Current assets 3,120,888,791.00 4,986,884,853.00 5,365,708,393.00 5,801,121,537.00 6,954,929,184.00 8,334,671,204.00 Total assets 4,730,813,195.00 6,912,827,307.00 7,524,887,877.00 9,686,269,567.00 11,096,971,158.00 13,206,467,007.00 Equity Share capital 161,700,000.00 161,700,000.00 194,040,000.00 194,040,000.00 197,147,560.00 237,738,330.00 Share premium 250,022,474.00 250,022,474.00 250,022,474.00 250,022,474.00 298,788,486.00 321,892,801.00 Capital reserve 1,671,386.00 1,671,386.00 1,671,386.00 1,671,386.00 1,671,386.00 1,671,386.00 Revaluation surplus 294,901,646.00 303,147,632.00 100,272,175.00 896,520,564.00 895,636,955.00 894,621,959.00 Available-for-sale reserve - - - 424,872,936.00 237,767,126.00 140,860,042.00 Retained earnings 563,800,530.00 1,488,114,482.00 2,284,194,871.00 2,691,050,437.00 3,136,486,047.00 3,484,501,642.00 Total equity 1,272,096,036.00 2,204,655,974.00 2,830,200,906.00 4,458,177,797.00 4,767,497,560.00 5,081,286,160.00 Liabilities Long-term liabilities 325,169,685.00 309,663,981.00 317,813,442.00 1,140,928,355.00 888,406,400.00 917,187,439.00 Deferred tax liabilities - - - - 125,011,848.00 106,310,663.00 Non-current liabilities 325,169,685.00 309,663,981.00 317,813,442.00 1,140,928,355.00 1,013,418,248.00 1,023,498,102.00 Bank overdraft 271,195,982.00 732,188,602.00 319,340,738.00 230,296,089.00 905,029,397.00 1,374,097,512.00 Short term bank loan 1,142,396,717.00 1,816,568,620.00 1,856,398,264.00 2,264,558,838.00 2,487,707,979.00 3,856,614,632.00 Long term bank loan- current portion 62,504,602.00 104,776,269.00 61,292,714.00 295,781,565.00 256,410,862.00 313,862,328.00 Trade payables 132,277,207.00 325,560,055.00 377,164,502.00 211,838,314.00 221,220,224.00 318,773,624.00 Other payables 478,332,706.00 469,811,403.00 1,149,121,470.00 665,636,419.00 939,541,226.00 856,449,976.00 Inter-company payables 758,658,669.00 709,609,851.00 57,749,189.00 69,556,334.00 289,071,143.00 172,929,856.00 Obligation under finance lease-current portion 10,220,408.00 5,718,892.00 1,839,801.00 523,990.00 652,878.00 761,582.00 Current tax liability 277,961,183.00 236,550,474.00 353,966,851.00 348,971,867.00 216,421,641.00 208,193,234.00 Current liability 3,133,547,474.00 4,400,784,166.00 4,176,873,529.00 4,087,163,416.00 5,316,055,350.00 7,101,682,744.00 Total liabilities 3,458,717,159.00 4,710,448,147.00 4,494,686,971.00 5,228,091,771.00 6,329,473,598.00 8,125,180,846.00 Advanced Chemical Industries Limited From 2007 to 2012
Transcript of FIN 423 final33333
Statement of Financial position
Amount in Taka Amount in Taka Amount in Taka Amount in Taka Amount in Taka Amount in Taka
2007 2008 2009 2010 2011 2012
Assets
Property plant and equipment
At cost/revalution 1,327,151,308.00 1,669,956,000.00 1,829,790,619.00 1,813,315,763.00 2,545,580,924.00 2,975,419,918.00
Accumulated depreciation 467,726,369.00 549,379,587.00 654,029,893.00 57,071,200.00 214,159,844.00 402,190,536.00
859,424,939.00 1,120,576,413.00 1,175,760,726.00 1,756,244,563.00 2,331,421,080.00 2,573,229,382.00
Capital work-in-progress 213,870,224.00 135,098,300.00 106,130,728.00 678,876,604.00 611,541,022.00 889,671,313.00
1,073,295,163.00 1,255,674,713.00 1,281,891,454.00 2,435,121,167.00 2,942,962,102.00 3,462,900,695.00
Intangible assets - - - 2,335,201.00 1,816,269.00 1,297,337.00
Long-term investment 536,629,241.00 670,267,741.00 877,288,030.00 1,447,691,662.00 1,197,263,603.00 1,407,597,771.00
Non-current assets 1,609,924,404.00 1,925,942,454.00 2,159,179,484.00 3,885,148,030.00 4,142,041,974.00 4,871,795,803.00
Inventories 1,091,397,629.00 2,085,053,250.00 1,596,524,690.00 1,716,072,609.00 1,770,481,777.00 2,128,984,396.00
Trade receivables 898,891,044.00 1,304,815,553.00 1,161,296,363.00 1,017,539,096.00 1,131,611,820.00 1,292,368,456.00
Other receivables 136,565,703.00 81,605,053.00 69,510,356.00 134,442,146.00 138,454,704.00 107,406,234.00
Advances, deposits and prepayments 179,761,041.00 245,796,966.00 368,143,911.00 414,326,518.00 522,847,653.00 460,184,564.00
Advances income tax 205,661,524.00 177,028,869.00 283,104,430.00 222,974,570.00 122,788,615.00 150,489,441.00
Inter-company receivable 551,416,377.00 862,058,775.00 1,169,264,620.00 2,141,326,463.00 3,045,084,692.00 4,033,776,402.00
Cash and cash equivalents 57,195,473.00 211,924,637.00 717,864,023.00 154,440,135.00 223,659,923.00 161,461,711.00
Assets classified as held for sale - 18,601,750.00 - - - -
Current assets 3,120,888,791.00 4,986,884,853.00 5,365,708,393.00 5,801,121,537.00 6,954,929,184.00 8,334,671,204.00
Total assets 4,730,813,195.00 6,912,827,307.00 7,524,887,877.00 9,686,269,567.00 11,096,971,158.00 13,206,467,007.00
Equity
Share capital 161,700,000.00 161,700,000.00 194,040,000.00 194,040,000.00 197,147,560.00 237,738,330.00
Share premium 250,022,474.00 250,022,474.00 250,022,474.00 250,022,474.00 298,788,486.00 321,892,801.00
Capital reserve 1,671,386.00 1,671,386.00 1,671,386.00 1,671,386.00 1,671,386.00 1,671,386.00
Revaluation surplus 294,901,646.00 303,147,632.00 100,272,175.00 896,520,564.00 895,636,955.00 894,621,959.00
Available-for-sale reserve - - - 424,872,936.00 237,767,126.00 140,860,042.00
Retained earnings 563,800,530.00 1,488,114,482.00 2,284,194,871.00 2,691,050,437.00 3,136,486,047.00 3,484,501,642.00
Total equity 1,272,096,036.00 2,204,655,974.00 2,830,200,906.00 4,458,177,797.00 4,767,497,560.00 5,081,286,160.00
Liabilities
Long-term liabilities 325,169,685.00 309,663,981.00 317,813,442.00 1,140,928,355.00 888,406,400.00 917,187,439.00
Deferred tax liabilities - - - - 125,011,848.00 106,310,663.00
Non-current liabilities 325,169,685.00 309,663,981.00 317,813,442.00 1,140,928,355.00 1,013,418,248.00 1,023,498,102.00
Bank overdraft 271,195,982.00 732,188,602.00 319,340,738.00 230,296,089.00 905,029,397.00 1,374,097,512.00
Short term bank loan 1,142,396,717.00 1,816,568,620.00 1,856,398,264.00 2,264,558,838.00 2,487,707,979.00 3,856,614,632.00
Long term bank loan- current portion 62,504,602.00 104,776,269.00 61,292,714.00 295,781,565.00 256,410,862.00 313,862,328.00
Trade payables 132,277,207.00 325,560,055.00 377,164,502.00 211,838,314.00 221,220,224.00 318,773,624.00
Other payables 478,332,706.00 469,811,403.00 1,149,121,470.00 665,636,419.00 939,541,226.00 856,449,976.00
Inter-company payables 758,658,669.00 709,609,851.00 57,749,189.00 69,556,334.00 289,071,143.00 172,929,856.00
Obligation under finance lease-current portion 10,220,408.00 5,718,892.00 1,839,801.00 523,990.00 652,878.00 761,582.00
Current tax liability 277,961,183.00 236,550,474.00 353,966,851.00 348,971,867.00 216,421,641.00 208,193,234.00
Current liability 3,133,547,474.00 4,400,784,166.00 4,176,873,529.00 4,087,163,416.00 5,316,055,350.00 7,101,682,744.00
Total liabilities 3,458,717,159.00 4,710,448,147.00 4,494,686,971.00 5,228,091,771.00 6,329,473,598.00 8,125,180,846.00
Advanced Chemical Industries Limited
From 2007 to 2012
Total equity and liabilities 4,730,813,195.00 6,915,104,121.00 7,324,887,877.00 9,686,269,568.00 11,096,971,158.00 13,206,467,006.00
Advanced Chemical Industries Limited
2007 2008
Amount in Taka Amount in Taka
Revenue 4,917,304,331 7,365,103,541
Cost of sales 3,250,711,677 5,086,311,724
Gross profit 1,666,592,654 2,278,791,817
Administrative, selling and distribution expenses 1,235,098,936 1,629,967,083
Operating profit 431,493,718 648,824,734
Other income 23,346,716 58,209,036
Profit from sale of share 118,818,000 779,634,140
573,658,434 1,486,667,910
Financing cost 119,087,159 280,811,155
454,571,275 1,205,856,755
Provision for contribution to WPPF 22,728,564 21,261,132
Profit before income tax 431,842,711 1,184,595,623
Income tax expenses
Current tax expense 124,518,231 98,683,532
Deferred tax expense 5,710,733 9,245,208
118,807,498 107,928,740
Net profit after tax for the year 313,035,213 1,076,666,883
Earnings per share
Basic earnings per share 19.36 66.52
Diluted earnings per share - -
Advanced Chemical Industries Limited
2009 2010 2011 2012
Amount in Taka Amount in Taka Amount in Taka Amount in Taka
7,228,289,966 7,915,400,279 8,513,841,846 9,680,061,562
4,862,554,832 5,094,561,620 5,352,860,199 6,089,878,323
2,365,735,134 2,820,838,659 3,160,981,647 3,590,183,239
1,719,222,750 1,919,655,805 2,193,597,248 2,670,135,457
646,512,384 901,182,854 967,384,399 920,047,782
43,083,330 86,240,840 99,755,402 137,921,467
654,561,881 - - -
1,344,157,595 987,423,694 1,067,139,801 1,057,969,249
212,744,711 136,849,107 126,842,315 282,555,490
1,131,412,884 850,574,587 940,297,486 775,413,759
23,842,550 42,528,729 47,014,874 38,770,688
1,107,570,334 808,045,858 893,282,612 736,643,071
117,416,377 213,842,650 194,212,347 199,460,929
3,511,274 2,613,194 17,941,192 7,933,731
120,927,651 216,455,844 212,153,539 191,527,198
986,642,683 591,590,014 681,129,073 545,115,873
50.85 30.49 34.64 22.94
- 29.40 34.09 22.79
Income StatementFrom 2007 to 2012
Advanced Chemical Industries Limited
2007 2008
Net profit after tax for the year 313,035,213.00 1,076,666,883.00
Long-term liabilities 325,169,685.00 309,663,981.00
Short term bank loan 1,142,396,717.00 1,816,568,620.00
Total Term Loan 1,467,566,402.00 2,126,232,601.00
Interest Expenses 139,249,313.00 319,095,946.00
Rate(%) 9.49% 15.01%
Share capital 161,700,000.00 161,700,000.00
Issued Share 16,170,000.00 16,170,000.00
Total Cash Dividend Paid 137,445,000.00 194,040,000.00
Dividend per share (Taka) 8.50 12.00
Dividend (%) 85.0% 120.0%
total(%) 94.49% 135.01%
Asset Value Y1 Asset Value Y2
497,058,048.78 766,131,325.87
EE for Y1 EE for Y2
582,108,490.09 983,020,788.74
Economic Earning
Advanced Chemical Industries Limited
2009 2010 2011 2012
986,642,683.00 591,590,014.00 681,129,073.00 545,115,873.00
317,813,442.00 1,140,928,355.00 888,406,400.00 917,187,439.00
1,856,398,264.00 2,264,558,838.00 2,487,707,979.00 3,856,614,632.00
2,174,211,706.00 3,405,487,193.00 3,376,114,379.00 4,773,802,071.00
309,236,495.00 214,765,893.00 285,641,399.00 172,094,475.00
14.22% 6.31% 8.46% 3.60%
194,040,000.00 194,040,000.00 197,147,560.00 237,738,330.00
19,404,000.00 19,404,000.00 19,714,756.00 23,773,833.00
203,742,000.00 232,848,000.00 197,147,560.00 237,738,330.00
10.50 12.00 10.00 10.00
105.0% 120.0% 100.0% 100.0%
119.22% 126.31% 108.46% 103.60%
Asset Value Y3 Asset Value Y4 Asset Value Y5 Asset Value Y6
672,485,231.61 482,735,314.80 458,238,118.36 267,732,096.03
EE for Y3 EE for Y4 EE for Y5 EE for Y6
796,892,766.19 567,092,817.56 490,623,050.66 277,383,776.97
Economic Earning
Amount in Taka
2007
Revnues from sale of goods & service 1,666,592,654.00
Operting expense 1,235,098,936.00
Operating income from continuing operations 431,493,718.00
Other income & Revenues 23,346,716
Recurring income befor interest & tax from continuing operations 454,840,434.00
Finance cost 119,087,159.00
Recurring(pretax) income from continuing operations 335,753,275.00
Unusal or infrequent items 22,728,564.00
Pretax earnings from continuing operations 313,024,711.00
Income tax expense 118,807,498.00
Net income from continuing operations 194,217,213.00
Income from discountinued operation -
Extraordiary items 118,818,000.00
Cumulative effect of accpunting changes -
Net income 313,035,213.00
Statement of suggested income
Amount in Taka Amount in Taka Amount in Taka Amount in Taka Amount in Taka
2008 2009 2010 2011 2012
2,278,791,817.00 2,365,735,134.00 2,820,838,659.00 3,160,981,647.00 3,590,183,239.00
1,629,967,083.00 1,719,222,750.00 1,919,655,805.00 2,193,597,248.00 2,670,135,457.00
648,824,734.00 646,512,384.00 901,182,854.00 967,384,399.00 920,047,782.00
58,209,036 43,083,330 86,240,840 99,755,402 137,921,467
707,033,770.00 689,595,714.00 987,423,694.00 1,067,139,801.00 1,057,969,249.00
280,811,155.00 212,744,711.00 136,849,107.00 126,842,315.00 282,555,490.00
426,222,615.00 476,851,003.00 850,574,587.00 940,297,486.00 775,413,759.00
21,261,132.00 23,842,550.00 42,528,729.00 47,014,874.00 38,770,688.00
404,961,483.00 453,008,453.00 808,045,858.00 893,282,612.00 736,643,071.00
107,928,740.00 120,927,651.00 216,455,844.00 212,153,539.00 191,527,198.00
297,032,743.00 332,080,802.00 591,590,014.00 681,129,073.00 545,115,873.00
- - - - -
779,634,140.00 654,561,881.00 - - -
- - - - -
1,076,666,883.00 986,642,683.00 591,590,014.00 681,129,073.00 545,115,873.00
Advanced Chemical Industries Limited
From 2007 to 2012
Statement of Financial positionfrom 2007 to 2012
Taka in'000 Taka in'000 Taka in'000 Taka in'000 Taka in'000 Taka in'000
2007 2008 2009 2010 2011 2012
Assets
Non-current assets
Property plant and equipment 318,105.00 326,467.00 348,185.00 368,102.00 480,662.00 497,830.00
Deferred tax asset 18,883.00 17,423.00 18,403.00 22,005.00 - -
336,988.00 343,890.00 366,588.00 390,107.00 480,662.00 497,830.00
Current assets
Inventories 425,381.00 596,205.00 610,525.00 695,231.00 1,138,844.00 1,059,544.00
Trade and other receivables 284,837.00 420,316.00 409,464.00 462,904.00 211,364.00 487,398.00
Cash and cash equivalents 21,281.00 1,937.00 314,295.00 666,043.00 770,584.00 1,019,434.00
731,499.00 1,018,458.00 1,334,284.00 1,824,178.00 2,120,792.00 2,566,376.00
Total assets 1,068,487.00 1,362,348.00 1,700,872.00 2,214,285.00 2,601,454.00 3,064,206.00
Equity
Share capital 120,485.00 120,465.00 120,465.00 120,465.00 120,465.00 120,465.00
Capital reserve 59,742.00 59,742.00 59,742.00 59,645.00 166.00 166.00
Revaluation reserves - - - - 59,479.00 59,479.00
General reserves 5,000.00 5,000.00 5,000.00 5,000.00 5,000.00 5,000.00
Retained earnings 614,177.00 727,003.00 978,511.00 1,196,041.00 1,237,180.00 1,300,450.00
Total equity 799,404.00 912,210.00 1,163,718.00 1,381,151.00 1,422,290.00 1,485,560.00
Liabilities
Obligation under finace lease 3,637.00 1,300.00 4,939.00 3,639.00 26,938.00 22,403.00
Retirement benefit obligation 68,331.00 68,811.00 66,919.00 80,020.00 82,139.00 83,874.00
Deferred tax liabilities 39,500.00 36,028.00 36,769.00 46,079.00 35,901.00 38,512.00
Total non-current liabilities 111,468.00 106,139.00 108,627.00 129,738.00 144,978.00 144,789.00
Trade and other payables 174,266.00 328,495.00 361,463.00 632,879.00 995,094.00 1,369,468.00
Obligation under finance lease 3,310.00 2,337.00 1,173.00 1,298.00 6,623.00 7,735.00
Current tax liability 19,961.00 13,167.00 66,521.00 69,219.00 32,469.00 56,654.00
Current liability 157,615.00 343,999.00 429,157.00 703,396.00 1,034,186.00 1,433,857.00
Total liabilities 269,083.00 450,138.00 537,784.00 833,134.00 1,179,164.00 1,578,646.00
Total equity and liabilities 1,068,487.00 1,362,348.00 1,701,502.00 2,214,285.00 2,601,454.00 3,064,206.00
GlaxoSmithkline
Taka in '000 Taka in '000 Taka in '000 Taka in '000 Taka in '000 Taka in '000
2007 2008 2009 2010 2011 2012
Revenue 1,589,090 1,888,105 3,023,672 3,632,095 4,735,121 5,553,812
Cost of sales 1,246,477 1,416,432 2,079,389 2,389,742 3,386,670 3,964,900
Gross profit 342,613 471,673 944,283 1,242,353 1,348,451 1,588,912
Operating expenses
Selling expenses 137,078 174,935 396,326 557,808 748,174 1,065,900
Distribution expanses 65,010 5,879 3,139 7,372 8,261 21,365
Administrative expenses 70,081 82,667 119,889 142,717 187,216 141,904
Other income 8,618 4,436 6,930 4,141 12,126 15,927
Total 263,551 259,045 512,424 703,756 931,525 1,213,242
Profit from operations 79,062 212,628 431,859 538,597 416,926 375,670
Financing income 2,642 408 7,794 17,983 52,163 60,341
Finance costs 4,584 8,427 831 820 3,759 5,149
Profit before charging WPPF 77,120 204,609 438,822 555,760 465,330 430,862
Allocation for WPPF - - - - - 21,523
Profit before taxation 77,120 204,609 438,822 555,760 465,330 409,339
Income tax expenses 32,072 61,660 115,035 142,583 183,262 165,372
Profit for the year 45,048 142,949 323,787 413,177 282,068 243,967
Earnings per share
Basic and Diluted 3.74 11.87 26.88 34.05 23.42 20.25
GlaxoSmithkline
Income StatementFrom 2007 to 2012
Taka in'000 Taka in'000 Taka in'000
2007 2008 2009
Profit for the year 45,048.00 142,949.00 323,787.00
Obligation under finace lease(long term) 3,637.00 1,300.00 4,939.00
Obligation under finance lease(Short term) 3,310.00 2,337.00 1,173.00
Total Term Loan 6,947.00 3,637.00 6,112.00
Interest Expenses 857.00 754.00 831.00
Rate(%) 12.34% 20.73% 13.60%
Share capital 120,485.00 120,465.00 120,465.00
Issued Share 12,048.50 12,046.50 12,046.50
Total Cash Dividend Paid 30,121.25 72,279.00 192,744.00
Dividend per share (Taka) 2.50 6.00 16.00
Dividend (%) 25.00% 60.00% 160.00%
total(%) 37.34% 80.73% 173.60%
Asset Value Y1 Asset Value Y2 Asset Value Y3
99,448.96 143,129.01 179,886.37
EE for Y1 EE for Y2 EE for Y3
88,728.05 179,706.35 327,602.18
GlaxoSmithklineEconomic Earning
Taka in'000 Taka in'000 Taka in'000
2010 2011 2012
410,177.00 282,068.00 243,967.00
3,639.00 26,938.00 22,403.00
1,298.00 6,623.00 7,735.00
4,937.00 33,561.00 30,138.00
820.00 3,759.00 5,149.00
16.61% 11.20% 17.08%
120,465.00 120,465.00 120,465.00
12,046.50 12,046.50 12,046.50
240,930.00 180,697.50 180,697.50
20.00 15.00 15.00
200.00% 150.00% 150.00%
216.61% 161.20% 167.08%
Asset Value Y4 Asset Value Y5 Asset Value Y6
183,701.55 142,189.61 91,344.42
EE for Y4 EE for Y5 EE for Y6
368,665.06 231,222.81 152,622.58
GlaxoSmithklineEconomic Earning
Amount in 000 Amount in 000
2007 2008
Revnues from sale of goods & service 342,613.00 471,673.00
Operting expense 272,169.00 263,481.00
Operating income from continuing operations 70,444.00 208,192.00
Other income & Revenues 8,618 4,436
Recurring income befor interest & tax from continuing operations 79,062.00 212,628.00
Finance cost 4,584.00 8,427.00
Recurring(pretax) income from continuing operations 74,478.00 204,201.00
Unusal or infrequent items - -
Pretax earnings from continuing operations 74,478.00 204,201.00
Income tax expense 32,072.00 61,660.00
Net income from continuing operations 42,406.00 142,541.00
Income from discountinued operation - -
Extraordiary items 2,642.00 408.00
Cumulative effect of accpunting changes - -
Net income 45,048.00 142,949.00
From 2007 to 2012
Statement of suggested income
Amount in 000 Amount in 000 Amount in 000 Amount in 000
2009 2010 2011 2012
944,283.00 1,242,353.00 1,348,451.00 1,588,912.00
519,354.00 707,897.00 943,651.00 1,229,169.00
424,929.00 534,456.00 404,800.00 359,743.00
6,930 4,141 12,126 15,927
431,859.00 538,597.00 416,926.00 375,670.00
831.00 820.00 3,759.00 5,149.00
431,028.00 537,777.00 413,167.00 370,521.00
- - - 21,523
431,028.00 537,777.00 413,167.00 348,998.00
115,035.00 142,583.00 183,262.00 165,372.00
315,993.00 395,194.00 229,905.00 183,626.00
- - - -
7,794.00 17,983.00 52,163.00 60,341.00
- - - -
323,787.00 413,177.00 282,068.00 243,967.00
GlaxoSmithkline
From 2007 to 2012
Phama Aids Limited
Statement of Financial Position
From 2007 to 2013
PHARMA AIDS LIMITED
Financial position
From 2008 to 2013
Amount in Taka Amount in Taka Amount in Taka Amount in Taka Amount in Taka Amount in Taka
2007-2008 2008-2009 2009-2010 2010-2011 2011-2012 2012-2013
ASSETS
Non-Current Assets
Property, plant and Equipment 56,506,438.00 55,693,383.00 50,788,261.00 47,227,630.00 43,167,794.00 78,881,772.00
Current Assets 34,599,041.00 45,908,843.00 48,774,500.00 65,815,432.00 93,278,968.00 73,679,058.00
Inventories 4,763,553.00 7,726,864.00 6,955,268.00 7,639,356.00 8,475,253.00 8,482,725.00
Trade and Other Receivable 18,441,921.00 24,753,213.00 26,897,045.00 37,793,156.00 50,595,110.00 45,290,478.00
Advance, Deposit & Prepayments 7,406,961.00 11,823,375.00 11,798,421.00 15,696,020.00 16,393,115.00 18,332,686.00
Goods-in-Transit 2,394,175.00 405,490.00 935,723.00 869,119.00 15,085,538.00 782,723.00
Cash and Cash Equivalent 1,592,431.00 1,199,901.00 2,188,043.00 3,817,781.00 2,729,952.00 790,446.00
TOTAL ASSETS 91,105,479.00 101,602,226.00 99,562,761.00 113,043,062.00 136,446,762.00 152,560,830.00
EQUITY AND LIABILITIES
Shareholders' Equity 53,914,769.00 63,288,831.00 66,722,598.00 74,058,817.00 82,055,295.00 86,383,385.00
Issued Share Capital 5,200,000.00 5,200,000.00 5,200,000.00 31,200,000.00 31,200,000.00 31,200,000.00
Tax Holiday Reserve - - 2,867,808.00 2,867,808.00 2,867,808.00 2,867,808.00
Retained Earnings 48,714,769.00 58,088,831.00 58,654,790.00 39,991,009.00 47,987,487.00 52,315,577.00
Current Liabilities 37,190,710.00 38,313,395.00 32,840,163.00 38,984,245.00 54,391,467.00 66,177,445.00
Trade Payable 3,808,632.00 2,973,106.00 2,688,148.00 3,017,662.00 2,964,755.00 3,422,475.00
Short Term Borrowing 9,614,841.00 7,359,556.00 8,481,504.00 4,986,558.00 7,765,093.00 23,513,767.00
Cash Credit 8,016,670.00 10,823,168.00 5,750,808.00 4,935,718.00 10,995,838.00 12,868,481.00
Liabilities For Expenses 4,561,129.00 2,961,356.00 3,024,960.00 3,337,714.00 4,265,163.00 6,547,371.00
Dividend Payable 3,479,480.00 4,155,663.00 3,708,238.00 9,928,028.00 13,215,419.00 7,503,991.00
Income Tax Payable 6,917,000.00 9,162,099.00 8,630,074.00 11,597,960.00 12,954,994.00 11,567,830.00
Liabilities For WPPF 792,958.00 878,447.00 556,431.00 1,180,605.00 2,230,205.00 753,530.00
TOTAL EQUITY AND LIABILITIES 91,105,479.00 101,602,226.00 99,562,761.00 113,043,062.00 136,446,762.00 152,560,830.00
Phama Aids Limited
Statement of Financial Position
From 2007 to 2013
Phama Aids Limited
Statement of Financial Position
From 2007 to 2013
Phama Aids Limited
Statement of Financial Position
From 2007 to 2013
Amount in Taka Amount in Taka Amount in Taka
2007-2008 2008-2009 2009-2010
Net Sales Revenue 77,953,431 93,965,621 68,738,716
Cost of Goods Sold 54,087,805 68,510,396 51,076,754
Gross Profit 23,865,626 25,455,225 17,661,962
Operating Expenses:
Administration and Selling Expenses 6,939,818 8,191,145 8,848,214
Profit From Operation 16,925,808 17,264,080 8,813,748
Other Income 17,268.00 37,793.00 51,543
Finance Cost 1,985,789 2,045,042 1,897,244
Profit Before Contribution to WPPF 14,957,287 15,256,831 6,968,047
Contribution to WPPF @5% 712,252 726,516.00 331,812
Profit Before Tax 14,245,035 14,530,315 6,636,235
Income Tax Expenses 3,525,646.00 3,596,253.00 1,642,468
Profit After Tax for the year 10,719,389 10,934,062 4,993,767
Other Comprehensive Income --- ---
Total Comprehensive Income for the year 10,719,389.00 10,934,062.00 4,993,767
Earning Per Share 3.44 3.51 1.60
Amount in Taka Amount in Taka Amount in Taka
2010-2011 2011-2012 2012-2013
97,588,294 108,289,653 97,615,975
65,855,702 72,706,938 74,404,663
31,732,592 35,582,715 23,211,312
10,559,764 11,091,386 12,400,293
21,172,828 24,491,329 10,811,019
105,113 81,455 107,907
1,899,031 2,531,186 4,650,658
19,378,910 22,041,598 6,268,268
922,805 1,049,600 298,489
18,456,105 20,991,998 5,969,779
4,567,886 5,195,520 1,641,689
13,888,219 15,796,478 4,328,090
--- --- ---
13,888,219 15,796,478 4,328,090
4.45 5.06 1.39
PHARMA AIDS LIMITEDStatement of Comprehensive Income
From 2008 to 2013
2007-2008 2008-2009 2009-2010
Profit for the year 10,719,389.00 10,934,062.00 4,993,767.00
Long-term liabilities - - -
Short term bank loan 9,614,841.00 7,359,556.00 8,481,504.00
Total Term Loan 9,614,841.00 7,359,556.00 8,481,504.00
Interest Expenses 1,971,810.00 2,027,551.00 1,878,591.00
Rate(%) 20.51% 27.55% 22.15%
Share capital 5,200,000.00 5,200,000.00 5,200,000.00
Issued Share 520,000.00 520,000.00 520,000.00
Total Cash Dividend Paid 1,560,000.00 1,560,000.00 1,560,000.00
Dividend per share (Taka) 3.00 3.00 3.00
Dividend (%) 30% 30% 30%
total(%) 50.51% 57.55% 52.15%
Asset Value Y1 Asset Value Y2 Asset Value Y3
17,526,976.81 16,162,194.00 14,208,637.69
EE for Y1 EE for Y2 EE for Y3
9,354,606.19 8,980,505.69 7,729,639.36
PHARMA AIDS LIMITED
Economic Earning
2010-2011 2011-2012 2012-2013
13,888,219.00 15,796,478.50 4,328,090.00
- - -
4,986,558.00 7,765,093.00 23,513,767.00
4,986,558.00 7,765,093.00 23,513,767.00
1,873,098.00 2,480,862.00 4,619,904.00
37.56% 31.95% 19.65%
31,200,000.00 31,200,000.00 31,200,000.00
3,120,000.00 3,120,000.00 3,120,000.00
6,552,000.00 7,800,000.00 4,680,000.00
2.10 2.50 1.50
21% 25% 15%
58.56% 56.95% 34.65%
Asset Value Y4 Asset Value Y5 Asset Value Y6
16,944,510.05 12,451,981.28 3,214,381.99
EE for Y4 EE for Y5 EE for Y6
9,395,690.23 6,558,879.21 1,113,708.01
PHARMA AIDS LIMITED
Economic Earning
Amount in Taka Amount in Taka
2007-2008 2008-2009
Revnues from sale of goods & service 23,865,626.00 25,455,225.00
Operting expense 6,939,818.00 8,191,145.00
Operating income from continuing operations 16,925,808.00 17,264,080.00
Other income & Revenues 17,268.00 37,793.00 Recurring income befor interest & tax from continuing operations 16,943,076.00 17,301,873.00
Finance cost 1,985,789 2,045,042
Recurring(pretax) income from continuing operations 14,957,287.00 15,256,831.00
Unusal or infrequent items 712,252 726,516.00 Pretax earnings from continuing operations 14,245,035.00 14,530,315.00
Income tax expense 3,525,646.00 3,596,253.00 Net income from continuing operations 10,719,389.00 10,934,062.00
Income from discountinued operation - -
Extraordiary items - -
Cumulative effect of accpunting changes - -
Net income 10,719,389.00 10,934,062.00
From 2007 to 2012 Amount in Taka Amount in Taka Amount in Taka Amount in Taka
2009-2010 2010-2011 2011-2012 2012-2013
17,661,962.00 31,732,592.00 35,582,715.00 23,211,312.00
8,848,214.00 10,559,764.00 11,091,386.00 12,400,293.00
8,813,748.00 21,172,828.00 24,491,329.00 10,811,019.00
51,543 105,113 81,455 107,907
8,865,291.00 21,277,941.00 24,572,784.00 10,918,926.00
1,897,244 1,899,031 2,531,186 4,650,658
6,968,047.00 19,378,910.00 22,041,598.00 6,268,268.00
331,812 922,805 1,049,600 298,489
6,636,235.00 18,456,105.00 20,991,998.00 5,969,779.00
1,642,468 4,567,886 5,195,520 1,641,689
4,993,767.00 13,888,219.00 15,796,478.00 4,328,090.00
- - - -
- - - -
- - - -
4,993,767.00 13,888,219.00 15,796,478.00 4,328,090.00
Statement of suggested income
PHARMA AIDS LIMITED
ACI GSK
Amount in Taka Amount in Taka 000
2012 2012
Assets
Property plant and equipment
At cost/revalution 2,975,419,918.00
Accumulated depreciation 402,190,536.00
2,573,229,382.00 497,830.00
Capital work-in-progress 889,671,313.00 -
3,462,900,695.00 497,830.00
Intangible assets 1,297,337.00 -
Long-term investment 1,407,597,771.00 -
Non-current assets 4,871,795,803.00 497,830.00
Inventories 2,128,984,396.00 1,059,544.00
Trade receivables 1,292,368,456.00 487,398.00
Other receivables 107,406,234.00
Advances, deposits and prepayments 460,184,564.00
Advances income tax 150,489,441.00
Inter-company receivable 4,033,776,402.00
Cash and cash equivalents 161,461,711.00 1,019,434.00
Assets classified as held for sale -
Current assets 8,334,671,204.00 2,566,376.00
Total assets 13,206,467,007.00 3,064,206.00
Equity
Share capital 237,738,330.00 120,465.00
Share premium 321,892,801.00
Capital reserve 1,671,386.00 166.00
Revaluation surplus 894,621,959.00 59,479.00
Available-for-sale reserve 140,860,042.00 5,000.00
Retained earnings 3,484,501,642.00 1,300,450.00
Total equity 5,081,286,160.00 1,485,560.00
Liabilities
Long-term liabilities 917,187,439.00 106,277.00
Deferred tax liabilities 106,310,663.00 38,512.00
Non-current liabilities 1,023,498,102.00 144,789.00
Bank overdraft 1,374,097,512.00
Short term bank loan 3,856,614,632.00
Long term bank loan- current portion 313,862,328.00
Cross-Sectional Comparisons
Trade payables 318,773,624.00 1,369,468.00
Other payables 856,449,976.00
Inter-company payables 172,929,856.00 -
Obligation under finance lease-current portion 761,582.00 7,735.00
Current tax liability 208,193,234.00 56,654.00
Current liability 7,101,682,744.00 1,433,857.00
Total liabilities 8,125,180,846.00 1,578,646.00
Total equity and liabilities 13,206,467,006.00 3,064,206.00
1. Current Asset Vs. Current Liability liquedity point of view : From liquidity point of views GSK is more liquid (84% /47%) than others company .
2.Fixed Asset Vs. Total Asset : Pharma Aids having more profit generating ability (52%) than others company .
3.Total Liability Vs. Total Asset solvancy point of view: From solvency point of views Pharma Aids is more solvencies (45%) than other company
4.Total Asset Vs. Total Equity : Pharma Aids equity base more strong (55%) than other company
Balance Sheet
Pharma Aids ACI GSK Pharma Aids
Amount in Taka Amount in Taka Amount in Taka 000 Amount in Taka
2012 2012 2012 2012
23% 0% 0%
3% 0% 0%
78,881,772.00 19% 16% 52%
782,723.00 7% 0% 1%
79,664,495.00 26% 16% 52%
- 0% 0% 0%
- 11% 0% 0%
79,664,495.00 37% 16% 52%
8,482,725.00 16% 35% 6%
45,290,478.00 10% 16% 30%
1% 0% 0%
18,332,686.00 3% 0% 12%
1% 0% 0%
31% 0% 0%
790,446.00 1% 33% 1%
72,896,335.00 63% 84% 48%
152,560,830.00 100% 100% 100%
31,200,000.00 2% 4% 20%
2% 0% 0%
0% 0% 0%
7% 2% 0%
753,530.00 1% 0% 0%
52,315,577.00 26% 42% 34%
84,269,107.00 38% 48% 55%
- 7% 3% 0%
2,867,808.00 1% 1% 2%
2,867,808.00 8% 5% 2%
12,868,481.00 10% 0% 8%
23,513,767.00 29% 0% 15%
6,547,371.00 2% 0% 4%
Cross-Sectional Comparisons
3,422,475.00 2% 45% 2%
7,503,991.00 6% 0% 5%
1% 0% 0%
0% 0% 0%
11,567,830.00 2% 2% 8%
65,423,915.00 54% 47% 43%
68,291,723.00 62% 52% 45%
152,560,830.00 100% 100% 100%
1. Current Asset Vs. Current Liability liquedity point of view : From liquidity point of views GSK is more liquid (84% /47%) than others company .
2.Fixed Asset Vs. Total Asset : Pharma Aids having more profit generating ability (52%) than others company .
3.Total Liability Vs. Total Asset solvancy point of view: From solvency point of views Pharma Aids is more solvencies (45%) than other company
ACIAmount in Taka
2012
Revenue 9,680,061,562 Cost of sales 6,089,878,323
Gross profit 3,590,183,239 Administrative, selling and distribution expenses 2,670,135,457
Operating profit 920,047,782 Other income 137,921,467
1,057,969,249 Financing cost 282,555,490
775,413,759 Provision for contribution to WPPF 38,770,688
Profit before income tax 736,643,071
Income tax expenses
Current tax expense 199,460,929
Deferred tax expense 7,933,731
191,527,198
Net profit after tax for the year 545,115,873
1. Cost of good sole Vs. Sales : Gross profitability ACI gross earnings ability more (63%) than other company
2. Operating income Vs.Sales : Pharma Aids operating earning ability more (11%) than other company
3. Income before tax Vs. Sales: ACI (8%) company earnings before tax is strong than other company
4. Net income Vs. Sales : ACI (6%) company earnings is strong than other company
Cross-Sectional Comparisons
Income Statement
GSK Pharma Aids ACI GSK Pharma AidsAmount in 000 Amount in Taka Amount in Taka Amount in 000 Amount in Taka
2012 2012-2013 2012 2012 2012-2013
5,553,812 97,615,975 100% 100% 100%
3,964,900 74,404,663 63% 71% 76%
1,588,912 23,211,312 37% 29% 24%
1,229,169 12,400,293 28% 22% 13%
359,743 10,811,019 10% 6% 11%
76,268 107,907 1% 1% 0%
436,011 10,918,926 11% 8% 11%
5,149 4,650,658 3% 0% 5%
430,862 6,268,268 8% 8% 6%
21,523 298,489 0% 0% 0%
409,339 5,969,779 8% 7% 6%
2% 0% 0%
0% 0% 0%
165,372 1,641,689 2% 3% 2%
243,967 4,328,090 6% 4% 4%
1. Cost of good sole Vs. Sales : Gross profitability ACI gross earnings ability more (63%) than other company
2. Operating income Vs.Sales : Pharma Aids operating earning ability more (11%) than other company
3. Income before tax Vs. Sales: ACI (8%) company earnings before tax is strong than other company
Cross-Sectional Comparisons
Amount in Taka Amount in Taka
2007 2008
Assets
Property plant and equipment
At cost/revalution 100% 126%
Accumulated depreciation 100% 117%
100% 130%
Capital work-in-progress 100% 63%
100% 117%
Intangible assets 0% 0%
Long-term investment 100% 125%
Non-current assets 100% 120%
Inventories 100% 191%
Trade receivables 100% 145%
Other receivables 100% 60%
Advances, deposits and prepayments 100% 137%
Advances income tax 100% 86%
Inter-company receivable 100% 156%
Cash and cash equivalents 100% 371%
Assets classified as held for sale 0% 100%
Current assets 100% 160%
Total assets 100% 146%
Equity
Share capital 100% 100%
Share premium 100% 100%
Capital reserve 100% 100%
Revaluation surplus 100% 103%
Available-for-sale reserve 0% 0%
Retained earnings 100% 264%
Total equity 100% 173%
Liabilities
Long-term liabilities 100% 95%
Deferred tax liabilities 0% 0%
Non-current liabilities 100% 95%
Bank overdraft 100% 270%
Short term bank loan 100% 159%
Long term bank loan- current portion 100% 168%
Advanced Chemical Industries Limited
Comparisons Over Time
Trade payables 100% 246%
Other payables 100% 98%
Inter-company payables 100% 94%
Obligation under finance lease-current portion 100% 56%
Current tax liability 100% 85%
Current liability 100% 140%
Total liabilities 100% 136%
Total equity and liabilities 100% 146%
1. Current Asset Vs. Current Liability liquedity point of view : From liquidity point of views ACI 2012 is more liquid (267% /227%) than others over The period .
2.Fixed Asset Vs. Total Asset : ACI 2012 having more profit generating ability (299%) than others over The period .
3.Total Liability Vs. Total Asset solvancy point of view: From solvency point of views ACI 2009 is more solvencies (130%) than other over The period
4.Total Asset Vs. Total Equity : ACI 2012 equity base more strong (399%) than other over The period
Amount in Taka Amount in Taka Amount in Taka Amount in Taka
2009 2010 2011 2012
138% 137% 192% 224%
140% 12% 46% 86%
137% 204% 271% 299%
50% 317% 286% 416%
119% 227% 274% 323%
0% 100% 78% 56%
163% 270% 223% 262%
134% 241% 257% 303%
146% 157% 162% 195%
129% 113% 126% 144%
51% 98% 101% 79%
205% 230% 291% 256%
138% 108% 60% 73%
212% 388% 552% 732%
1255% 270% 391% 282%
0% 0% 0% 0%
172% 186% 223% 267%
159% 205% 235% 279%
120% 120% 122% 147%
100% 100% 120% 129%
100% 100% 100% 100%
34% 304% 304% 303%
0% 100% 56% 33%
405% 477% 556% 618%
222% 350% 375% 399%
98% 351% 273% 282%
0% 0% 100% 85%
98% 351% 312% 315%
118% 85% 334% 507%
163% 198% 218% 338%
98% 473% 410% 502%
Advanced Chemical Industries Limited
From 2007 to 2012
Comparisons Over Time
285% 160% 167% 241%
240% 139% 196% 179%
8% 9% 38% 23%
18% 5% 6% 7%
127% 126% 78% 75%
133% 130% 170% 227%
130% 151% 183% 235%
155% 205% 235% 279%
1. Current Asset Vs. Current Liability liquedity point of view : From liquidity point of views ACI 2012 is more liquid (267% /227%) than others over The period .
2.Fixed Asset Vs. Total Asset : ACI 2012 having more profit generating ability (299%) than others over The period .
3.Total Liability Vs. Total Asset solvancy point of view: From solvency point of views ACI 2009 is more solvencies (130%) than other over The period
4.Total Asset Vs. Total Equity : ACI 2012 equity base more strong (399%) than other over The period
Advanced Chemical Industries Limited
2007 2008 2009
Amount in Taka Amount in Taka Amount in Taka
Revenue 100% 150% 147%
Cost of sales 100% 156% 150%
Gross profit 100% 137% 142%
Administrative, selling and distribution expenses 100% 132% 139%
Operating profit 100% 150% 150%
Other income 100% 249% 185%
Profit from sale of share 100% 656% 551%
100% 259% 234%
Financing cost 100% 236% 179%
100% 265% 249%
Provision for contribution to WPPF 100% 94% 105%
Profit before income tax 100% 274% 256%
Income tax expenses
Current tax expense 100% 79% 94%
Deferred tax expense 100% 162% 61%
100% 91% 102%
Net profit after tax for the year 100% 344% 315%
1. Cost of good sole Vs. Sales : Gross profitability ACI 2009 gross earnings ability more (150%) than other over The period
2. Operating income Vs.Sales : ACI 2011 operating earning ability more (224%) than other over The period
3. Income before tax Vs. Sales: ACI 2008 (274%) company earnings before tax is strong than other over The period
4. Net income Vs. Sales : ACI 2008 (344%) company earnings is strong than other over The period
From 2007 to 2012
Comparisons Over Time
Advanced Chemical Industries Limited
2010 2011 2012
Amount in Taka Amount in Taka Amount in Taka
161% 173% 197%
157% 165% 187%
169% 190% 215%
155% 178% 216%
209% 224% 213%
369% 427% 591%
0% 0% 0%
172% 186% 184%
115% 107% 237%
187% 207% 171%
187% 207% 171%
187% 207% 171%
172% 156% 160%
46% 314% 139%
182% 179% 161%
189% 218% 174%
1. Cost of good sole Vs. Sales : Gross profitability ACI 2009 gross earnings ability more (150%) than other over The period
3. Income before tax Vs. Sales: ACI 2008 (274%) company earnings before tax is strong than other over The period
From 2007 to 2012
Comparisons Over Time
from 2007 to 2012
Taka in'000 Taka in'000 Taka in'000 Taka in'000
2007 2008 2009 2010
Assets
Non-current assets
Property plant and equipment 100% 103% 109% 116%
Deferred tax asset 100% 92% 97% 117%
100% 102% 109% 116%
Current assets
Inventories 100% 140% 144% 163%
Trade and other receivables 100% 148% 144% 163%
Cash and cash equivalents 100% 9% 1477% 3130%
100% 139% 182% 249%
Total assets 100% 128% 159% 207%
Equity
Share capital 100% 100% 100% 100%
Capital reserve 100% 100% 100% 100%
Revaluation reserves 0% 0% 0% 0%
General reserves 100% 100% 100% 100%
Retained earnings 100% 118% 159% 195%
Total equity 100% 114% 146% 173%
Liabilities
Obligation under finace lease 100% 36% 136% 100%
Retirement benefit obligation 100% 101% 98% 117%
Deferred tax liabilities 100% 91% 93% 117%
Total non-current liabilities 100% 95% 97% 116%
Trade and other payables 100% 189% 207% 363%
Obligation under finance lease 100% 71% 35% 39%
Current tax liability 100% 66% 333% 347%
Current liability 100% 218% 272% 446%
Total liabilities 100% 167% 200% 310%
Total equity and liabilities 100% 128% 159% 207%
1. Current Asset Vs. Current Liability liquedity point of view : From liquidity point of views GSK 2012 is more liquid (351% /910%) than others over The period .
GlaxoSmithklineComparisons Over Time
2.Fixed Asset Vs. Total Asset : GSK 2012 having more profit generating ability (148%) than others over The period .
3.Total Liability Vs. Total Asset solvancy point of view: From solvency point of views GSK 2008 is more solvencies (167%) than other overThe period
4.Total Asset Vs. Total Equity : GSK 2012 equity base more strong (186%) than other over The period
from 2007 to 2012
Taka in'000 Taka in'000
2011 2012
151% 156%
0% 0%
143% 148%
268% 249%
74% 171%
3621% 4790%
290% 351%
243% 287%
100% 100%
0% 0%
100% 100%
100% 100%
201% 212%
178% 186%
741% 616%
120% 123%
91% 97%
130% 130%
571% 786%
200% 234%
163% 284%
656% 910%
438% 587%
243% 287%
1. Current Asset Vs. Current Liability liquedity point of view : From liquidity point of views GSK 2012 is more liquid (351% /910%) than others over The period .
2.Fixed Asset Vs. Total Asset : GSK 2012 having more profit generating ability (148%) than others over The period .
3.Total Liability Vs. Total Asset solvancy point of view: From solvency point of views GSK 2008 is more solvencies (167%) than other overThe period
Taka in '000 Taka in '000 Taka in '000 Taka in '000 Taka in '000
2007 2008 2009 2010 2011
Revenue 100% 119% 190% 229% 298%
Cost of sales 100% 114% 167% 192% 272%
Gross profit 100% 138% 276% 363% 394%
Operating expenses
Selling expenses 100% 128% 289% 407% 546%
Distribution expanses 100% 9% 5% 11% 13%
Administrative expenses 100% 118% 171% 204% 267%
Other income 100% 51% 80% 48% 141%
Total 100% 98% 194% 267% 353%
Profit from operations 100% 269% 546% 681% 527%
Financing income 100% 15% 295% 681% 1974%
Finance costs 100% 184% 18% 18% 82%
Profit before charging WPPF 100% 265% 569% 721% 603%
Allocation for WPPF 0% 0% 0% 0% 0%
Profit before taxation 100% 265% 569% 721% 603%
Income tax expenses 100% 192% 359% 445% 571%
Profit for the year 100% 317% 719% 917% 626%
1. Cost of good sole Vs. Sales : Gross profitability GSK 2008 gross earnings ability more (114%) than other over The period
2. Operating income Vs.Sales : GSK 2010 operating earning ability more (681%) than other over The period
3. Income before tax Vs. Sales: GSK 2010 (721%) company earnings before tax is strong than other over The period
4. Net income Vs. Sales : GSK 2010 (917%) company earnings is strong than other over The period
GlaxoSmithklineComparisons Over Time
From 2007 to 2012
Taka in '000
2012
349%
318%
464%
778%
33%
202%
185%
460%
475%
2284%
112%
559%
100%
531%
516%
542%
1. Cost of good sole Vs. Sales : Gross profitability GSK 2008 gross earnings ability more (114%) than other over The period
2. Operating income Vs.Sales : GSK 2010 operating earning ability more (681%) than other over The period
3. Income before tax Vs. Sales: GSK 2010 (721%) company earnings before tax is strong than other over The period
PHARMA AIDS LIMITED
From 2008 to 2013
Amount in Taka Amount in Taka Amount in Taka
2007-2008 2008-2009 2009-2010
ASSETS
Non-Current Assets
Property, plant and Equipment 100% 99% 90%
Current Assets 100% 133% 141%
Inventories 100% 162% 146%
Trade and Other Receivable 100% 134% 146%
Advance, Deposit & Prepayments 100% 160% 159%
Goods-in-Transit 100% 17% 39%
Cash and Cash Equivalent 100% 75% 137%
TOTAL ASSETS 100% 112% 109%
EQUITY AND LIABILITIES
Shareholders' Equity 100% 117% 124%
Issued Share Capital 100% 100% 100%
Tax Holiday Reserve 0% 0% 100%
Retained Earnings 100% 119% 120%
Current Liabilities 100% 103% 88%
Trade Payable 100% 78% 71%
Short Term Borrowing 100% 77% 88%
Cash Credit 100% 135% 72%
Liabilities For Expenses 100% 65% 66%
Dividend Payable 100% 119% 107%
Income Tax Payable 100% 132% 125%
Liabilities For WPPF 100% 111% 70%
TOTAL EQUITY AND LIABILITIES 100% 112% 109%
Comparisons Over Time
1. Current Asset Vs. Current Liability liquedity point of view : From liquidity point of views Pharma Aids2011- 2012 is more liquid (270% /146%) than others over The period .
2.Fixed Asset Vs. Total Asset : Pharma Aids 2012- 2013 having more profit generating ability (140%) than others over The period .
3.Total Liability Vs. Total Asset solvancy point of view: From solvency point of views Pharma Aids 2009-2010 is more solvencies (109%) than other over The period
4.Total Asset Vs. Total Equity : Pharma Aids 2012-2013 equity base more strong (160%) than other over The period
PHARMA AIDS LIMITED
From 2008 to 2013
Amount in Taka Amount in Taka Amount in Taka
2010-2011 2011-2012 2012-2013
84% 76% 140%
190% 270% 213%
160% 178% 178%
205% 274% 246%
212% 221% 248%
36% 630% 33%
240% 171% 50%
124% 150% 167%
137% 152% 160%
600% 600% 600%
100% 100% 100%
82% 99% 107%
105% 146% 178%
79% 78% 90%
52% 81% 245%
62% 137% 161%
73% 94% 144%
285% 380% 216%
168% 187% 167%
149% 281% 95%
124% 150% 167%
Comparisons Over Time
1. Current Asset Vs. Current Liability liquedity point of view : From liquidity point of views Pharma Aids2011- 2012 is more liquid (270% /146%) than others over The period .
2.Fixed Asset Vs. Total Asset : Pharma Aids 2012- 2013 having more profit generating ability (140%) than others over The period .
3.Total Liability Vs. Total Asset solvancy point of view: From solvency point of views Pharma Aids 2009-2010 is more solvencies (109%) than other over The period
4.Total Asset Vs. Total Equity : Pharma Aids 2012-2013 equity base more strong (160%) than other over The period
Amount in Taka Amount in Taka Amount in Taka
2007-2008 2008-2009 2009-2010
Net Sales Revenue 100% 121% 88%
Cost of Goods Sold 100% 127% 94%
Gross Profit 100% 107% 74%
Operating Expenses:
Administration and Selling Expenses 100% 118% 127%
Profit From Operation 100% 102% 52%
Other Income 100% 219% 298%
Finance Cost 100% 103% 96%
Profit Before Contribution to WPPF 100% 102% 47%
Contribution to WPPF @5% 100% 102% 47%
Profit Before Tax 100% 102% 47%
Income Tax Expenses 100% 102% 47%
Profit After Tax for the year 100% 102% 47%
Other Comprehensive Income 0% 0% 0%
Total Comprehensive Income for the year 100% 102% 47%
1. Cost of good sole Vs. Sales : Gross profitability Pharma Aids 2009-2010 gross earnings ability more (94%) than other over The period
2. Operating income Vs.Sales : Pharma Aids 2011-2012 operating earning ability more (145%) than other over The period
3. Income before tax Vs. Sales: Pharma Aids 2011-2012 (147%) company earnings before tax is strong than other over The period
4. Net income Vs. Sales : Pharma Aids 2011-2012 (147%) company earnings is strong than other over The period
PHARMA AIDS LIMITED
Amount in Taka Amount in Taka Amount in Taka
2010-2011 2011-2012 2012-2013
125% 139% 125%
122% 134% 138%
133% 149% 97%
152% 160% 179%
125% 145% 64%
609% 472% 625%
96% 127% 234%
130% 147% 42%
130% 147% 42%
130% 147% 42%
130% 147% 47%
130% 147% 40%
0% 0% 0%
130% 147% 40%
1. Cost of good sole Vs. Sales : Gross profitability Pharma Aids 2009-2010 gross earnings ability more (94%) than other over The period
2. Operating income Vs.Sales : Pharma Aids 2011-2012 operating earning ability more (145%) than other over The period
3. Income before tax Vs. Sales: Pharma Aids 2011-2012 (147%) company earnings before tax is strong than other over The period
4. Net income Vs. Sales : Pharma Aids 2011-2012 (147%) company earnings is strong than other over The period
Comparisons Over Time
From 2008 to 2013
PHARMA AIDS LIMITED
Activity Analysis
A. Short-Term Activity Ratio:
1. Inventory Turnover Ratio = Cost Of Good Sold/Inventory
Comment:
2. Receivables Turnover Ratio = Sales/Receivable
Comment:
3. Payable Turnover = Purchase/Account Payable
Comment:
4. Working Capital Turnover = Sales/Working Capital
Comment:
B. Long-Term Activity Ratio:
1. Fixed Assets Turnover Ratio = Sales/Fixed Assets
Comment:
2. Total Assets Turnover Ratio = Sales/Total Assets
Comment:
Liquidity Analysis
1. Current Ratio = Current Assets/Current Liabilities
Comment:
2. Quick Ratio = Cash+Mar.Sec+Account Receiables/Current Liabilities
Comment:
3. Cash Ratio = Cash+Marketable Securities/Current Liabilities
Comment:
4. Cash flow From Operation Ratio = Cash flow From Operation /Current Liabilities
Comment:
5. Difensive Interval = 365*Cash+ Cash+Mar.Sec+Account Receiables/Project Expenditure
Comment:
Long-Term Debt & Solvency Analysis
1. debt To Equity = Total Debt/Total Equity
Comment:
2. Use Book Value Or Market Value To Compute Debt Ratio = Total Debt At Book Value/Equity To Market Value
Comment:
3. Times Interest Earned = Earning Before Interest & Taxes(EBIT)/Interest Expense
Comment:
4. Fixed Charge Coverage = Earning Before Fixed Charges & Taxes/Fixed Charges
Comment:
5. Capital Expenditure Ratio = Cash From Operation(CFO)/Capital Expenditure
Comment:
6. Cash From Operation(CFO)-TO-Debt Ratio = Cash From Operation/Total Debt
Comment:
Profitability Analysis
A. Return On Sales:
1. Gross Profit Margin = Gross Profit/Sales
Comment:
2. Operating Income = Operating Income/Sales
Comment:
3. Profit Margin = EBIT/Sales
Comment:
4. Pretax Margin = Earning Before Tax(EBT)/Sales
Comment:
5. Net Profit Margin = Net Income/Sales
Comment:
B. Return On Investment(ROI)
1. Return On Assets(ROA) = Net Income/Total Assets
Comment:
2. Return On Total Capital = EBIT/(Total Debt+Stockholders Equity)
Comment:
3. Return On Equity (ROE) = Net Income/Stockholders Equity
Comment:
4. Return On Common Equity(ROCE) = Net Income-Preferred Dividends/Common Equity
Comment:
Operating & Financial Leverage
1. Contribution Margin Ratio = 1-Variable Costs/sales
Comment:
2. Operating Leverage Effect(OLE) = Contribution Margin Ratio/Return On Sales
Comment:
3. Financial Leverage Effect = Operating Income/Net Income
Comment:
Advanced Chemical Industries Limited
Amount in Taka Amount in Taka Amount in Taka Amount in Taka
2007 2008 2009 2010
2.98 2.44 3.05 2.97
(388.45) 12.57 6.08 4.62
5.72
1.04 1.07 0.96 0.82
Ratio Analysis
2007 to 2012
0.995960271 1.133180966 1.284623141 1.419351503
2. Use Book Value Or Market Value To Compute Debt Ratio = Total Debt At Book Value/Equity To Market Value
4.817130905
0.338924041 0.309403908 0.327288355 0.356373469
0.116661161
0.087821026
0.063659923 0.146184894 0.136497386 0.074739115
0.07 0.16 0.13 0.06
0.25
1.832568383
Amount in Taka Amount in Taka
2011 2012
3.02 2.86
5.19 7.85
0.77 0.73
Ratio Analysis
1.308287579 1.173619198
0.371275589 0.37088434
0.080002552 0.056313265
0.06 0.04
Activity Analysis
A. Short-Term Activity Ratio:
1. Inventory Turnover Ratio = Cost Of Good Sold/Inventory
Comment:
2. Receivables Turnover Ratio = Sales/Receivable
Comment:
3. Payable Turnover = Purchase/Account Payable
Comment:
4. Working Capital Turnover = Sales/Working Capital
Comment:
B. Long-Term Activity Ratio:
1. Fixed Assets Turnover Ratio = Sales/Fixed Assets
Comment:
2. Total Assets Turnover Ratio = Sales/Total Assets
Comment:
Liquidity Analysis
1. Current Ratio = Current Assets/Current Liabilities
Comment:
2. Quick Ratio = Cash+Mar.Sec+Account Receiables/Current Liabilities
Comment:
3. Cash Ratio = Cash+Marketable Securities/Current Liabilities
Comment:
4. Cash flow From Operation Ratio = Cash flow From Operation /Current Liabilities
Comment:
5. Difensive Interval = 365*Cash+ Cash+Mar.Sec+Account Receiables/Project Expenditure
Comment:
Long-Term Debt & Solvency Analysis
1. debt To Equity = Total Debt/Total Equity
Comment:
2. Use Book Value Or Market Value To Compute Debt Ratio = Total Debt At Book Value/Equity To Market Value
Comment:
3. Times Interest Earned = Earning Before Interest & Taxes(EBIT)/Interest Expense
Comment:
4. Fixed Charge Coverage = Earning Before Fixed Charges & Taxes/Fixed Charges
Comment:
5. Capital Expenditure Ratio = Cash From Operation(CFO)/Capital Expenditure
Comment:
6. Cash From Operation(CFO)-TO-Debt Ratio = Cash From Operation/Total Debt
Comment:
Profitability Analysis
A. Return On Sales:
1. Gross Profit Margin = Gross Profit/Sales
Comment:
2. Operating Income = Operating Income/Sales
Comment:
3. Profit Margin = EBIT/Sales
Comment:
4. Pretax Margin = Earning Before Tax(EBT)/Sales
Comment:
5. Net Profit Margin = Net Income/Sales
Comment:
B. Return On Investment(ROI)
1. Return On Assets(ROA) = Net Income/Total Assets
Comment:
2. Return On Total Capital = EBIT/(Total Debt+Stockholders Equity)
Comment:
3. Return On Equity (ROE) = Net Income/Stockholders Equity
Comment:
4. Return On Common Equity(ROCE) = Net Income-Preferred Dividends/Common Equity
Comment:
Operating & Financial Leverage
1. Contribution Margin Ratio = 1-Variable Costs/sales
Comment:
2. Operating Leverage Effect(OLE) = Contribution Margin Ratio/Return On Sales
Comment:
3. Financial Leverage Effect = Operating Income/Net Income
Comment:
Taka in'000 Taka in'000 Taka in'000 Taka in'000 Taka in'000
2007 2008 2009 2010 2011
2.93 2.38 3.41 3.44 2.97
5.58 4.49 7.38 7.85 22.40
7.15 8.13 4.36 5.99 4.48
2.77 2.80 3.34 3.24 4.36
4.72 5.49 8.25 9.31 9.85
0.86 0.92 0.69 0.86 0.79
GlaxoSmithkline
Ratio Analysis
2007 to 2012
4.6410494 2.9606423 3.1090813 2.5933869 2.0506872
1.94 1.23 1.69 1.60 0.95
0.1350189 0.0056308 0.7323544 0.9468962 0.7451116
1.67 (0.03) 0.74 0.45 0.32
0.0041406 0.0025619 0.001008 0.0009398 0.0046566
2. Use Book Value Or Market Value To Compute Debt Ratio = Total Debt At Book Value/Equity To Market Value 0.0041406 0.0025619 0.001008 0.0009398 0.0046566
17.823735 25.280171 529.06498 678.7561 124.7909
0.2156033 0.2498129 0.3122968 0.3420486 0.2847765
0.049753 0.1126145 0.142826 0.1482882 0.0880497
0.0514156 0.1128306 0.1454037 0.1532394 0.0990659
0.0485309 0.1083674 0.1451288 0.1530136 0.098272
0.0283483 0.0757103 0.107084 0.1137572 0.0595693
0.04 0.10 0.19 0.19 0.11
0.08 0.16 0.26 0.25 0.18
0.06 0.16 0.28 0.30 0.20
0.06 0.16 0.28 0.30 0.20
4.3334725 2.2183014 2.1865539 2.3066467 3.2342694
1.7550613 1.4874396 1.333775 1.3035503 1.4781046
Taka in'000
2012
3.74
11.39
3.32
4.90
11.16
0.64
1.789841
1.05
0.7109733
0.27
0.0052068
0.0052068
84.678773
0.2860939
0.0676418
0.0785066
0.0737042
0.0439278
0.08
0.14
0.16
0.16
4.2295419
1.5398394
Activity Analysis
A. Short-Term Activity Ratio:
1. Inventory Turnover Ratio = Cost Of Good Sold/Inventory
Comment:
2. Receivables Turnover Ratio = Sales/Receivable
Comment:
3. Payable Turnover = Purchase/Account Payable
Comment:
4. Working Capital Turnover = Sales/Working Capital
Comment:
B. Long-Term Activity Ratio:
1. Fixed Assets Turnover Ratio = Sales/Fixed Assets
Comment:
2. Total Assets Turnover Ratio = Sales/Total Assets
Comment:
Liquidity Analysis
1. Current Ratio = Current Assets/Current Liabilities
Comment:
2. Quick Ratio = Cash+Mar.Sec+Account Receiables/Current Liabilities
Comment:
3. Cash Ratio = Cash+Marketable Securities/Current Liabilities
Comment:
4. Cash flow From Operation Ratio = Cash flow From Operation /Current Liabilities
Comment:
5. Difensive Interval = 365(Cash+ Cash+Mar.Sec+Account Receiables/Project Expenditure)
Comment:
Long-Term Debt & Solvency Analysis
1. debt To Equity = Total Debt/Total Equity
Comment:
2. Use Book Value Or Market Value To Compute Debt Ratio = Total Debt At Book Value/Equity To Market Value
Comment:
3. Times Interest Earned = Earning Before Interest & Taxes(EBIT)/Interest Expense
Comment:
4. Fixed Charge Coverage = Earning Before Fixed Charges & Taxes/Fixed Charges
Comment:
5. Capital Expenditure Ratio = Cash From Operation(CFO)/Capital Expenditure
Comment:
6. Cash From Operation(CFO)-TO-Debt Ratio = Cash From Operation/Total Debt
Comment:
Profitability Analysis
A. Return On Sales:
1. Gross Profit Margin = Gross Profit/Sales
Comment:
2. Operating Income = Operating Income/Sales
Comment:
3. Profit Margin = EBIT/Sales
Comment:
4. Pretax Margin = Earning Before Tax(EBT)/Sales
Comment:
5. Net Profit Margin = Net Income/Sales
Comment:
B. Return On Investment(ROI)
1. Return On Assets(ROA) = Net Income/Total Assets
Comment:
2. Return On Total Capital = EBIT/(Total Debt+Stockholders Equity)
Comment:
3. Return On Equity (ROE) = Net Income/Stockholders Equity
Comment:
4. Return On Common Equity(ROCE) = Net Income-Preferred Dividends/Common Equity
Comment:
Operating & Financial Leverage
1. Contribution Margin Ratio = 1-Variable Costs/sales
Comment:
2. Operating Leverage Effect(OLE) = Contribution Margin Ratio/Return On Sales
Comment:
3. Financial Leverage Effect = Operating Income/Net Income
Comment:
Amount in Taka Amount in Taka Amount in Taka Amount in Taka
2007-2008 2008-2009 2009-2010 2010-2011
11.35 8.87 7.34 8.62
4.23 3.80 2.56 2.58
14.20 24.04 18.71 22.05
(30.08) 12.37 4.31 3.64
1.38 1.69 1.35 2.07
0.86 0.92 0.69 0.86
PHARMA AIDS LIMITED
Ratio Analysis
2008 to 2012
0.930314076 1.198245235 1.485208828 1.688257192
0.60 0.69 0.91 1.09
0.042817978 0.031318055 0.066627044 0.097931382
0.19 0.03 0.02 0.05
0.178334085 0.116285226 0.127115914 0.067332401
2. Use Book Value Or Market Value To Compute Debt Ratio = Total Debt At Book Value/Equity To Market Value 0.33 0.29 0.21 0.13
8.532163286 8.460399835 4.672720536 11.20463068
0.306152349 0.270899343 0.256943438 0.325168017
0.217127172 0.183727621 0.128221016 0.216960735
0.22 0.18 0.13 0.22
0.182737755 0.154634374 0.0965429 0.18912212
0.14 0.12 0.07 0.14
0.117659104 0.107616363 0.050156976 0.122857774
0.19 0.17 0.09 0.19
0.198821013 0.17276448 0.074843713 0.187529582
1.39 1.30 0.25 0.13
1.410013986 1.474461715 2.003910482 1.498741311
1.58 1.58 1.76 1.52
Amount in Taka Amount in Taka
2011-2012 2012-2013
8.58 8.77
2.14 2.16
24.81 21.74
2.78 13.01
2.51 1.24
0.79 0.64
PHARMA AIDS LIMITED
Ratio Analysis
1.714955914 1.113356038
1.26 0.71
0.050190814 0.011944341
0.01 0.02
0.094632443 0.272202426
0.23 0.42
9.708011975 2.347823899
0.328588319 0.2377819
0.226164997 0.11075051
0.23 0.11
0.19385045 0.061155759
0.15 0.04
0.115770267 0.028369602
0.18 0.07
0.19251016 0.050103269
0.08 (0.10)
1.452869912 2.147005014
1.55 2.50
